mdlinx mdlinx
Latest (206) Full Text Articles (9654) Focus on Cancer Article Summary

Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
Journal of Nuclear Cardiology, 05/17/2012

Shaw LJ et al. – Patient management strategies that focus on ischemia resolution can be useful to guide the efficacy of near–term therapeutic approaches. A 1–year post–therapeutic intervention myocardial perfusion scan provides important information regarding prognosis in stable CAD patients with diabetes.

Methods
  • MPS was performed in 1,505 patients at 1–year following randomization.
  • MPS images were analyzed (masked to treatment) by a Nuclear Core Laboratory using a quantitative percent (%) of total, ischemic, and scarred myocardium.
  • Cox proportional hazards models were used to estimate the relationship between MPS variables and trial endpoints.

Results
  • At 1–year, nearly all REV patients underwent the assigned procedure; while 16% of those randomized to MED received coronary REV.
  • Patients randomized to REV exhibited fewer stress perfusion abnormalities than MED patients (P < .001).
  • CABG patients had more frequent ischemic and scarred myocardium encumbering ≥5% of the myocardium when compared to those receiving PCI.
  • Patients randomized to MED had more extensive ischemia and the median % of the myocardium with perfusion abnormalities was lower following REV (3% vs 9%, P = .01).
  • A total of 59% of REV patients had no inducible ischemia at 1–year compared to 49% of MED patients (P < .001).
  • Within the CABG stratum, those randomized to MED had the greatest rate of ischemic (P = .032) and scarred (P = .017) perfusion abnormalities.
  • At 1–year, more extensive and severe stress myocardial perfusion abnormalities were associated with higher 5–year rates of death and a combined endpoint of cardiac death or myocardial infarction (MI) rates (11.3%, 8.1%, 6.8%, for ≥10%, 5%–9.9%, and 1–4.9% abnormal myocardium at stress, respectively, P < .001).
  • In adjusted models, selected MPS variables were significantly associated with an increased hazard of cardiac death or MI (hazard ratio = 1.11 per 5% increase in abnormal myocardium at stress, P = .004).

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Last month's top read Top Articles of 2012

1 Walking Versus Running for Hypertension, Cholesterol, and Diabetes Mellitus Risk Reduction Arteriosclerosis, Thrombosis, and Vascular Biology, April 17, 2013    Clinical Article

2 Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Full Text New England Journal of Medicine, April 8, 2013    Continuing Medical Education    Free full text

3 Vitamin D Levels for Preventing Acute Coronary Syndrome and Mortality: Evidence of a Non-Linear Association Journal of Clinical Endocrinology and Metabolism, March 27, 2013    Clinical Article
Exclusive Author Commentary

4 Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants Full Text Clinical Cardiology, April 11, 2013    Free full text    Review Article    Clinical Article

5 Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials British Medical Journal, April 25, 2013    Evidence Based Medicine    Review Article

6 The Risk of Taking Ascorbic Acid JAMA Internal Medicine, February 5, 2013    Clinical Article

7 Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial The Lancet, April 18, 2013    Clinical Article

8 Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial Diabetes Care, April 9, 2013    Clinical Article

9 Enalapril And Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients with Malignant Hemopathies. The OVERCOME Trial JACC - Journal of the American College of Cardiology, April 12, 2013    Clinical Article

10 Drug Interactions with Grapefruit Juice Full Text British Journal of Medical Practitioners, February 12, 2013    Free full text    Clinical Article

11 Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial European Heart Journal, April 22, 2013    Clinical Article

12 Pulmonary hypertension: diagnosis and management British Medical Journal, April 23, 2013    Continuing Medical Education    Review Article

13 Infective Endocarditis New England Journal of Medicine, April 12, 2013    Clinical Article

14 Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels -- Results from a randomized trial European Journal of Internal Medicine , April 11, 2013    Clinical Article

15 Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement Annals of Internal Medicine, February 26, 2013    Clinical Guideline

16 Infective Endocarditis New England Journal of Medicine, April 24, 2013    Continuing Medical Education    Review Article

17 Osteoporosis treatment European Journal of Internal Medicine , April 24, 2013    Clinical Article

18 Bone mineral density testing: Is a T score enough to determine the screening interval? Full Text Cleveland Clinic Journal of Medicine, April 3, 2013    Continuing Medical Education    Free full text

19 The impact of coffee on health Maturitas, February 26, 2013    Clinical Article

20 Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials Full Text Cardiovascular Diabetology, April 12, 2013    Free full text    Clinical Article

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Other Topics in Internal Medicine

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close